Otsuka Pharmaceutical: Difference between revisions
No edit summary |
No edit summary |
||
| Line 70: | Line 70: | ||
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area. | In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area. | ||
In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million. | In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million. | ||
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion. | In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion. | ||